FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review
18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) and contrast-enhanced computed tomography (CT) can be used for response evaluation in metastatic breast cancer (MBC). In this study, we aimed to review literature comparing the PET Response Criteria...
Main Authors: | Fredrik Helland, Martine Hallin Henriksen, Oke Gerke, Marianne Vogsen, Poul Flemming Høilund-Carlsen, Malene Grubbe Hildebrandt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/9/3/106 |
Similar Items
-
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
by: Malene Grubbe Hildebrandt, et al.
Published: (2019-08-01) -
The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [<sup>18</sup>F]FDG-PET/CT and CE-CT
by: Rosa Gram-Nielsen, et al.
Published: (2023-10-01) -
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
by: Marianne Vogsen, et al.
Published: (2021-04-01) -
Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer
by: Mohammad Naghavi-Behzad, et al.
Published: (2021-08-01) -
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
by: Jonas S. Sørensen, et al.
Published: (2020-11-01)